Spherix Global Insights Launches Respiratory Franchise
News related to:Spherix Global Insights · 2 min read
Exton, PA, Sept. 21, 2026 /CourierPR/ -- Spherix Global Insights, a leading independent market intelligence and advisory firm serving the global life sciences industry, has expanded its research portfolio to include a dedicated Respiratory Franchise. This move, announced today, builds on the company’s two-year research in the therapeutic area, focusing on asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD).
The new Respiratory Franchise brings together Spherix’s established work with experienced researchers and a growing publication portfolio. The company has been conducting research for more than 15 consecutive months, supported by access to qualified allergists, immunologists, and pulmonologists across the U.S. and Europe. This extensive research provides a robust foundation for connecting insights across indications, specialties, and geographies, as Spherix continues to broaden its respiratory coverage.
Through the new franchise, Spherix will connect physician, patient, and payer perspectives with the therapeutic expertise needed to interpret findings for development, launch, market access, and brand strategy. Clients will have access to Spherix’s respiratory specialists for strategic working sessions, tailored research, prescriber analyses, and advisory support.
The 2026 Respiratory publication portfolio includes Market Dynamix™: Asthma, US and Market Dynamix™: Asthma, EU, providing insight into how treatment approaches, physician perceptions, unmet needs, and expectations for emerging therapies differ across the two regions. Spherix is also now providing the same deep insights and geographic perspective through Market Dynamix™: Chronic Obstructive Pulmonary Disease, US and Market Dynamix™: Chronic Obstructive Pulmonary Disease, EU.
The portfolio also includes Special Topix™: ILD in Rheumatology, US, which examines an important area of intersection between respiratory and rheumatologic care. Its inclusion reflects Spherix’s ability to maintain cross-franchise expertise while giving respiratory-focused research a distinct and clearly defined home.
The initial portfolio will expand as innovation advances and new client needs emerge, with opportunities to add respiratory indications, research formats, and stakeholder perspectives over time. The focused Respiratory Franchise reinforces Spherix’s commitment to investing in therapeutic areas where sustained research, specialist expertise, and historical context can provide clients with a more meaningful view of the market.
Spherix Global Insights operates ten dedicated therapeutic franchises, including Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Obesity, Oncology, Ophthalmology, Respiratory, and Rheumatology. Each franchise is staffed by hyper-focused experts who track these markets full-time, drawing on independently curated communities of vetted specialists, patients, and payers to deliver quarterly trending, launch tracking, chart audits, and KOL synthesis.
Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for leading brands, industry media, financial analysts, and patient advocacy groups for more than a decade.